SetPoint Medical Appoints Rohan Seth as Chief Financial Officer

Accomplished finance leader joins SetPoint Medical as it advances its development of a novel neuroimmune modulation platform for rheumatoid arthritis

VALENCIA, Calif.--(BUSINESS WIRE)-- SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced the appointment of Rohan Seth as Chief Financial Officer (CFO).

“I am excited to welcome Rohan to the SetPoint leadership team,” said Murthy Simhambhatla, Ph.D., President and CEO of SetPoint Medical. “Rohan’s proven track record of success in managing finance and business development functions will be instrumental as we continue to advance our therapeutic platform through clinical development.”

“I am honored to join the SetPoint team and strongly believe in the amazing value creation and life-changing therapeutic potential it offers for treatment of rheumatoid arthritis,” said Seth. “I look forward to working with the team to advance the company’s strategy and operational plans.”

Prior to SetPoint Medical, Seth served as the CFO at Cutera (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions. His prior experiences include VP of Finance for Global Orthopaedics Franchise at Smith & Nephew, Head of Finance for U.S. Surgical at Alcon Labs and various roles with increasing responsibilities at Stryker Corporation. Seth started his career in public accounting in Mumbai, India, and worked at the Whirlpool Corporation prior to his medical device industry roles.

Seth earned his Master of Business Administration from the University of Notre Dame’s Mendoza College of Business and completed his Bachelor of Commerce in Accounting and Auditing from the University of Mumbai’s M. M. K. College of Economics and Commerce. He is also a Chartered Accountant from the Institute of Chartered Accountants of India.

About SetPoint Medical

SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. For more information, visit www.setpointmedical.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230612005137/en/